Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/iSpecimen Inc./ 10-K

Annual Report · 10-K

iSpecimen Inc.

ISPCNASDAQEQUITYCurrent

Annual Report

Filed Apr 14, 2025Accepted Apr 14, 2025, 5:24 PM EDTCIK 1558569Accession 0001213900-25-031639
View company →Permanent SEC source ↗
Share

Company context

iSpecimen is a technology-driven company founded to address a critical challenge: how to connect life science researchers who need human biofluids, tissues, and living cells (“biospecimens”) for their research, with the billions of biospecimens available (but not easily accessible) in healthcare provider organizations worldwide. Our ground-breaking iSpecimen Marketplace platform was designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery.

Current securities

ISPCNASDAQ · EQUITY · Current

Recent company filings

  1. DEF 14A filingSep 14, 2026
  2. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 10, 2026
  3. PRE 14A filingSep 4, 2026
  4. Entry into a Material Definitive AgreementSep 4, 2026
  5. 8-K filingAug 31, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗